Skip to main content
. 2023 Sep 29;19(2):2257426. doi: 10.1080/21645515.2023.2257426

Table 3.

Impact of PCV20 versus PCV15 as SoC over 10 years.

Outcome PCV15 PCV20 Difference
Cases of IPD 44,824 39,265 −5,559
Cases of hospitalized pneumonia 3,357,540 3,254,564 −102,976
Cases of non-hospitalized pneumonia 11,325,104 11,283,803 −41,301
Cases of complex OM 35,441 33,351 −2,090
Cases of simple OM 3,039,726 2,886,061 −153,665
Number of deaths due to disease 234,806 227,540 −7,266
Payer perspective: total costs $57,270,492,746 $55,786,224,862 −$1,484,267,884
 Cost of doses $909,392,243 $991,476,031 $82,083,788
 Medical costs $56,240,055,653 $54,689,266,231 −$1,550,789,422
 Costs of lifetime sequalae $121,044,849 $105,482,600 −$15,562,249
Societal perspective: total costs $67,951,242,501 $66,159,121,040 −$1,792,121,460
QALYs 338,990,806 339,012,687 21,881
 QALY loss to Meningitis 84 74 −10
 QALY loss to Bacteremia 1,120 984 −136
 QALY loss to Non-invasive hospitalized pneumonia 108,660 105,490 −3170
 QALY loss to Non-hospitalized pneumonia 203,575 203,543 −32
 QALY loss to Complex OM 50 48 −2
 QALY loss to Simple OM 4,330 4,113 −217
 QALY loss to Deafness 21 18 −3
 QALY loss to Disability 22 19 −3
Payer Perspective: ICER per QALY     PCV20 Dominant
Societal Perspective: ICER per QALY     PCV20 Dominant

Abbreviations: ICER = incremental cost-effectiveness ratio; IPD = invasive pneumococcal disease; OM = otitis media; QALY = quality-adjusted life years; SoC = standard of care.

Costs are expressed in Canadian dollars.